Devices for continuous monitoring of glucose: update in technology

Ana María Gómez1
Diana Cristina Henao Carrillo1
Oscar Mauricio Muñoz Velandia2,3
1Endocrinology Unit, Hospital Universitario San Ignacio, Bogotá, Colombia; 2Department of Internal Medicine, Hospital Universitario San Ignacio, Bogotá, Colombia; 3Department of Clinical Epidemiology, Pontificia Universidad Javeriana, Faculty of Medicine, Bogotá, Colombia

Abstract: Continuous glucose monitoring (CGM) is a tool that allows constant evaluation of glycemic control, providing data such as the trend and fluctuation of interstitial glucose levels over time. In clinical practice, there are two modalities: the professional or retrospective and the personal or real-time CGM (RT-CGM). The latest-generation sensors are more accurate and sensitive for hypoglycemia, improving adherence to self-monitoring, which has allowed optimizing glycemic control. The development of algorithms that allow the suspension of the infusion of insulin during hypoglycemia gave rise to the integrated therapy or sensor-augmented insulin pump therapy with low glucose suspend, which has proven to be an effective and safe alternative in the treatment of diabetic patients with high risk of hypoglycemia. The objective of this review is to present the evidence of the advantages of RT-CGM, the clinical impact of integrated therapy, and cost-effectiveness of its implementation in the treatment of patients with diabetes mellitus.

Keywords: CGM, devices, hypoglycemia, SAPT, SAPT+LGS

Introduction
Since UK Prospective Diabetes Study1 and Diabetes Control and Complications Trial,2 the metabolic control has become the main tool to decrease the onset and progression of complications in diabetic patients. However, the cost of strict glycemic control is the increase of hypoglycemia, which makes it the principal barrier to achieve A1c goals.3

Self-monitoring of the blood glucose (SMBG) is still the most widely used method to evaluate glycemic control; although, several clinical studies have correlated the number of measurements with better metabolic control.3–6 However, as most of these are performed during the day, the information is limited to preprandial glucose measurement and its timing is defined by the patient, which makes it difficult to detect hypoglycemia, especially at night and does not always provide the best information for the clinician.7

There is a wide range of devices that allow the evaluation of interstitial glucose levels 24 h a day and provide additional information, such as the rate of change of glucose levels in relation to time. Table 1 summarizes different devices available.8

Numerical and clinical accuracy of continuous glucose monitoring devices
Professional continuous glucose monitoring (CGM) and real-time CGM (RT-CGM) are performed with transcutaneous electrochemical systems that evaluate the content of interstitial glucose. Measurements in this compartment differ in time and magnitude.
from the corresponding blood glucose values, and variations are greater when there are rapid changes in plasma glucose concentrations, and this is due to the physiological and instrumental time lag between the interstitial and blood glucose differences, which is about 13.5 min approximately.

For this reason, it is important to know how close the device measurements are to SMBG or the accuracy that is measured and reported for all glucose monitoring systems. There are many ways to assess sensor accuracy. There are several standards, one of them is the relative absolute difference value between capillary vs interstitial glucose divided by the reference value, in this case the capillary glucose, expressed as a percentage (mean absolute relative difference [MARD%]). Some systems fulfilled ISO 15197:2013 based on MARD% in the entire glycemic range, and the values were 13.2%±10.9% (Abbott Diabetes Care, Alameda, CA, USA), 16.8%±12.3% (Dexcom, San Diego, CA, USA), and 21.4%±17.6% (Medtronic, Northridge, CA, USA), respectively, during real-life conditions. However, these numerical methods are biased by the high volume of data handled. Therefore, they have created methods for analysis by clinical trends such as Consensus Error Grid, the strength of this method is measuring the safety and efficacy of a glucose monitoring system for making clinical decisions. This tool allows to identify the frequency of errors and the device performance according to the zones A, B, C, D, and E, which means that higher percentages in zone A or zones A+B indicate better performance of the device. Modifications in the calibration processes and algorithms of the devices have led to a significant improvement in the clinical aspect, making the percentage of determinations located in zones A and B to be between 76% and 89% for the lower values, and 94%–97% in the normo and hyperglycemia ranges. “Real-life” studies have reported a similar behavior with a global performance in areas A and B of 91.7%; in hypoglycemia (glycemia less than 70 mg/dL with or without symptoms) and hyperglycemia (glycemia greater than 180 mg/dL), values approximate those described in the literature (75.6% for hypoglycemia and 97.6% for hyperglycemia).

Continuous assessment of glucose concentration using a CGM device requires a reliable and reproducible method of calibration. There are two types of calibration: factory calibrated and patient calibrated. In the first one the wired enzyme sensor is calibrated in the factory and, therefore, requires no user calibration. In the second type these devices require calibration with capillary glucose, which should be performed after the sensor implantation.

In recent years, advances have been made with the aim of improving the accuracy of the measurement especially in

---

### Table 1 Devices available to monitor interstitial glucose levels

| Device | Type | Accuracy\(^\text{a}\) (MARD\%) | Calibration (n/day) | Sensor lifetime (days) | Observations |
|--------|------|-------------------------------|--------------------|----------------------|--------------|
| Medtronic (Northridge, CA, USA) | Professional Real time | X | 13.6 | 3 | 6 | Sensor Enlite, SAPT Minilink Hypoglycemia suspension Sensor Enlite, SAPT Guardian 2 link Sensor Enlite and Soft-sensor |
| MiniMed\(^\text{b}\) 640G with SmartGuard\(^\text{a}\) | X | 14.2 | 3 | 6 | |
| iPro\(^\text{a}\) Professional CGM system | X | 11 | 3 | 6 | |
| Roche (San Diego, CA, USA) | | | | |
| Dexcom\(^\text{c}\) G4 PLATINUM CGM\(^\text{a}\) | X | Adults: 13 Children:15 | 2 | 7 | |
| Medtronic (Northridge, CA, USA) | | | | |
| Abbott Diabetes Care (Alameda, CA, USA) | | | | |
| FreeStyle Libre Flash glucose monitoring system\(^\text{b}\) | X | 10 | No | 14 | It allows to measure interstitial glucose, the number of times the patient performs the scan. No alarms |
| FreeStyle Navigator II CGM system\(^\text{c}\) | X | 12.3 | 5\(^\text{a}\) | 5 | |
| FreeStyle Libre Pro | X | 11.1 | No | 14 | |

**Notes:** *Medtronic and Dexcom devices measure the interstitial glucose trend every 5 min.* **FreeStyle Navigator II CGM system requires four calibrations on day 1 and one calibration on day 3. In Abbot devices, the interstitial glucose readings are generated every minute.*

**Abbreviations:** CGM, continuous glucose monitoring; MARD%, mean absolute relative difference; SAPT, sensor augmented pump therapy.
hypoglycemia. New-generation sensors have greater precision (relative difference of absolute mean or MARD <10%), which reduces the difference between the measurement of interstitial glucose and capillary glucose and increases the sensitivity for the detection of hypoglycemia.\textsuperscript{6,18}

The device FreeStyle Libre Flash glucose monitoring system designed by Abbott Diabetes Care has a sensor calibrated in the factory, using wired enzyme technology (osmium mediator and enzyme glucose oxidase enzyme co-immobilized on an electrochemical sensor) that allows measuring interstitial glucose, as frequently as the number of times the patient performs the scan; however, it does not emit alarms that indicate the patient to take a specific action.\textsuperscript{19} The fact that this sensor does not require calibration with capillary blood glucose has been demonstrated to be feasible, resulting in accuracy metrics similar to other sensors. There is a correlation study made with this device compared to CGM Dexcom G4 Platinum, suggesting that the time spent in different glucose ranges, like hyper- and hypoglycemia, and indexes of glucose variability were not significantly different.\textsuperscript{20}

Medtronic and Dexcom have developed monitoring devices, with algorithms capable of creating an approximation to “real time,” based on the interstitial glucose trend. These systems inform the patient about the value and trends of interstitial glucose, causing the patient intervention to avoid hyper- and hypoglycemia.\textsuperscript{3,4,6,7} Devices like Paradigm\textsuperscript{®}, Veo\textsuperscript{™}, and MiniMed\textsuperscript{®} 640G with SmartGuard\textsuperscript{®} from Medtronic have the function low glucose suspend (LGS) in the case of the first device; the second device uses a predictive algorithm that allows it to suspend the infusion of insulin prior to hypoglycemia, and this kind of therapy is known as sensor-augmented insulin pump with low glucose suspend, SAP+LGS.\textsuperscript{6}

**RT-CGM and its impact on glycemic control**

Several controlled clinical studies, systematic reviews, and meta-analyses have documented the decreased benefit of glycosylated hemoglobin (A1c) in patients using RT-CGM compared to SMBG with a minimum capillary glucose measurement 4 times a day.\textsuperscript{3,6}

Table 2 summarizes the RT-CGM studies with reduction in A1c as the primary outcome. The JDRF (Juvenile Diabetes Research Foundation) used different devices (DexCom Seven, MiniMed Paradigm Real-Time Insulin Pump, and Continuous Glucose Monitoring System FreeStyle Navigator), while the STAR3 study compared MiniMed Paradigm REAL-Time System (Medtronic) vs multiple daily injection (MDI)+SMBG in patients diagnosed with type 1 diabetes (T1D) from different age groups including children. These studies reported a significant reduction in A1c of −0.53% (95% CI, 0.71%−0.35%, \(p<0.001\)) and −0.64% (95% CI, −0.7% to −0.4%, \(p<0.001\)), respectively, in favor of RT-CGM users. The RealTrend study was a controlled clinical trial comparing the efficacy of sensor-associated insulin pump therapy vs the use of sensorless insulin pump therapy; the group that used the sensor more than 70% of the time reduced the A1c in −0.41% (\(p<0.004\)).\textsuperscript{3,4,6} and similar studies have shown that the addition of RT-CGM to already established continuous subcutaneous insulin infusion (CSI) therapy led to an improvement of glycemic control.\textsuperscript{21} The reduction in A1c was significant from the third month; however, the time of sensor use is crucial to the success of CGM.\textsuperscript{22,21}

The subanalysis of the results considered the time of use of the sensor as a factor related to the reduction in A1c and the increase of the time in normoglycemia.\textsuperscript{4} In the JDFR the use of the sensor at least 6 days per week independent of the age of the patients was associated with reduction of −0.5% on average of A1c.\textsuperscript{4} In STAR3 a directly proportional relationship was established between the use time of the sensor and the reduction in A1c, describing a significant reduction in A1c in those subjects who used the sensor between 41% and 60% of the time, which doubled in subjects who used it more than 80% of the time.\textsuperscript{3}

In long-term studies, the use of SAP+LGS therapy has shown that the impact on metabolic control is observed early, between 3 and 5 months after initiation of therapy, and was maintained for 47±22.7 months of follow-up in −1.7% (95% CI, −1.59 to −1.90; \(p<0.001\)) with a low incidence of hypoglycemia, and a significant increase in the percentage of the population that met criteria for the composite outcome, which means A1c less than or equal to 7% in the absence of hypoglycemia (2.7%–42.3%, \(p<0.001\)).\textsuperscript{15} Similar findings have been described in other series, suggesting that the RT-CGM is a useful tool that allows achieving strict goals of metabolic control, with reduction of episodes of severe hypoglycemia.\textsuperscript{3,4,6,7}

**The role of RT-CGM in reducing hypoglycemia**

The American Diabetes Association (ADA) in the consensus published in January 2017 defined hypoglycemia as an episode of low glucose concentration that exposes the individual to potential harm, and is classified into three levels (Table 3).\textsuperscript{24}
Table 2 Summary of clinical studies with reduction of A1c using RT-CGM with different therapies as a primary outcome

| Reference | Population | Intervention | Follow-up (months) | No. of patients | Base A1c Total (% | CGM (%) | p-value A1c at the end of follow-up (%) | p-value | Observations |
|-----------|------------|--------------|--------------------|----------------|-------------------|--------|----------------------------------------|--------|-------------|
| Deiss et al | T1D, >14 years | CSI or MDI+RT-CGM | 3 | 156 | 52 | 9.5±1.1 | 8.5±1.7 | 0.003 | Device: Guardian RT. Average baseline SMBG per day were 4.6±1.4, 5.0±1.5, and 5.1±1.8 glucometries/day |
| JDRE | T1D, >25 years | CSI or MDI+RT-CGM biweekly | 6 | 98 | 52 | 9.7±1.3 | 9.3±1.0 | <0.001 | Devices: DexCom Seven (DexCom), the MiniMed Paradigm REAL-Time Insulin Pump and Continuous Glucose Monitoring System (Medtronic), or the FreeStyle Navigator (Abbott Diabetes Care) |
| Hirsch et al | T1D, 12–72 years | CSI+RT-CGM | 3 | 62 | 26 | 8.49±0.76 | 7.7±0.92 | <0.001 | Sensor use was 6 days/week in 83% of subjects >25 years old. Subjects without RT-CGM showed an increase (p<0.001) in hypoglycemia AUC during the blinded periods of the study. Subjects were categorized according to sensor use compliance and compared to the subjects with compliance. <60% showed statistically significant improvement in A1c |
| O'Connell et al | T1D, 13–40 years, well controlled | CSI+RT-CGM | 3 | 62 | 26 | 7.3±0.6 | 7.1±0.8 | <0.009 | Device: Paradigm 722 system |
| Real Trend | T1D | CSI+RT-CMG | 6 | 115 | 55 | 9.28±1.19 | 8.32±0.93 | 0.087 | Device: MiniMed Paradigm REAL-Time system, with instructions to wear CGM sensors at least 70% of the time vs conventional CSI therapy |
| STAR3 | T1D | CSI+CMG | 12 | 485 | 244 | 8.3±0.5 | 7.5±0.8 | <0.001 | Device: MiniMed Paradigm REAL-Time System, Medtronic 37% of patients achieve combined outcome |
| Haak T | T2D | CSI or MDI+RT-CMG | 6 | 224 | 149 | 8.7±0.97 | 8.2±0.09 | 0.0301 | Subjects <65 years, the drop in A1c was more pronounced in the intervention group. Reduction in 53% of time in hypoglycemia |
| Gomez AM | T1D | CSI or MDI+SMGB | 47 | 111 | 111 | 8.8±1.04 | 8.68±0.12 | <0.001 | “Real-life” data. 43.3% of patients achieve combined outcome during the follow-up |
| COMISAIR Study | T1D (>18 years) | Group 1: SAPT | 12 | 65 | 15 | 8.2±0.9 | 7.1±0.9 | <0.0025 | Use of sensor: 6 days/week vs SMBG 4 times/day |
| | | Group 2: MDI+RT-CGM | 12 | 8.5±1.1 | 7.2±0.8 | 0.0034 | Devices: Group 1: Paradigma VEO |
| | | Group 3 (control): CSI+SMGB or MDI+SMGB | 20 | 8.4±0.9 | 7.9±0.7 | 0.04 | Group 2: Dexcom G4 Platinum CGM system |

(Continued)
Clinically significant hypoglycemia is a common complication and one of the main barriers to achieving adequate metabolic control; also, the relationship between hypoglycemia and increased risk of death from cardiovascular causes has been described. Additionally, in T1D patients, the counterregulatory mechanisms mediated by different hormones, including glucagon, epinephrine, growth hormone, and cortisol, fail as beta cell function is lost, and this phenomenon has been associated with increased episodes of unawareness hypoglycemia (UH); this phenomenon usually appears between 5 and 10 years after diagnosis and increases in 25 times the risk of severe hypoglycemia, and of these episodes more than 50% occur during sleep. Severe hypoglycemia is the most serious and dreaded complication of insulin-treated patients; recurrent episodes are associated with an increased incidence of cardiovascular events, convulsions, cognitive loss, and impairment of quality of life (QoL). Many factors related to hypoglycemia have been described, including intensive insulin therapy, which triples episodes of hypoglycemia and increases episodes of severe hypoglycemia (62 vs 19 episodes/100 patient-years) when compared to conventional therapy.

There are different strategies to avoid hypoglycemia, and among them the structured patient education, individualized targets for high-risk patients, and SMBG, are cornerstones in order to prevent it; however, the use of CGM has been shown to reduce the frequency and duration of clinically significant hypoglycemia. The Flash glucose monitoring system, FreeStyle Libre, has become one of the strategies that are available to reduce the incidence of hypoglycemia. A multicenter, controlled study in T1D patients with adequate metabolic control showed a reduction of 50% of the time in clinically significant hypoglycemia (<55 mg/dL), with a reduction in the number of capillary glucose measurements of 5.5±2.0 to 0.5±0.7 glucometer/day although no significant changes were reported in A1c. A similar study conducted recently showed a significant reduction in the time below all hypoglycemic thresholds and the number of episodes in the intervention group compared with SMBG at 6 months of follow-up; this reduction was almost immediate as sensor-based results became visible to participants. Type 2 diabetes (T2D) patients in MDI or insulin infuser showed 53% reduction in time in clinically significant hypoglycemia (0.47±0.13 h/day [p=0.0006]), reduction in the number of capillary glucometer measurements of 3.8±1.4 to 0.3±0.7 glucometer/day, with a significant reduction in A1c levels in patients younger than 65 years. The clinically relevant reduction in hypoglycemia

| Reference | Population (months) | Intevention | Follow-up | No. of patients | Base A1c % | A1c at the end of follow-up | p-value |
|-----------|---------------------|-------------|-----------|----------------|-----------|-----------------------------|---------|
| DIAMOND Trial | >60 years | MDI-SMBG vs DIAMOND Trial | 6 | 116 | 8.64±0.6 | 8.45±0.9 | <0.001 |
| DIAMOND Trial | >60 years | MDI-SMBG vs DIAMOND Trial | 6 | 158 | 8.66±0.7 | 7.40±0.6 | <0.001 |
| DIAMOND Trial | >60 years | MDI-SMBG vs DIAMOND Trial | 6 | 153 | 8.66±0.7 | 7.40±0.6 | <0.001 |
| DIAMOND Trial | >60 years | MDI-SMBG vs DIAMOND Trial | 6 | 153 | 8.66±0.7 | 7.40±0.6 | <0.001 |
| DIAMOND Trial | >60 years | MDI-SMBG vs DIAMOND Trial | 6 | 153 | 8.66±0.7 | 7.40±0.6 | <0.001 |
| DIAMOND Trial | >60 years | MDI-SMBG vs DIAMOND Trial | 6 | 153 | 8.66±0.7 | 7.40±0.6 | <0.001 |
| DIAMOND Trial | >60 years | MDI-SMBG vs DIAMOND Trial | 6 | 153 | 8.66±0.7 | 7.40±0.6 | <0.001 |
| DIAMOND Trial | >60 years | MDI-SMBG vs DIAMOND Trial | 6 | 153 | 8.66±0.7 | 7.40±0.6 | <0.001 |
| DIAMOND Trial | >60 years | MDI-SMBG vs DIAMOND Trial | 6 | 153 | 8.66±0.7 | 7.40±0.6 | <0.001 |
| DIAMOND Trial | >60 years | MDI-SMBG vs DIAMOND Trial | 6 | 153 | 8.66±0.7 | 7.40±0.6 | <0.001 |
| DIAMOND Trial | >60 years | MDI-SMBG vs DIAMOND Trial | 6 | 153 | 8.66±0.7 | 7.40±0.6 | <0.001 |
| DIAMOND Trial | >60 years | MDI-SMBG vs DIAMOND Trial | 6 | 153 | 8.66±0.7 | 7.40±0.6 | <0.001 |

Abbreviations: CSII, continuous subcutaneous insulin infusion; MDI, multiple daily injection; RT-CGM, real-time continuous glucose monitoring; SAPT, sensor augmented pump therapy; SH, severe hypoglycemia; UH, unawareness hypoglycemia.
without depending on an alarm function or self-monitored blood glucose testing might have been achieved because of the adherence (>90%) and scanning frequency, which have been described with other devices.33

Initially, continuous monitoring systems informed the patient about the tendency of their glucose levels, with the goal of correcting hyper- or hypoglycemia. Current devices use SAP+LGS to prevent hypoglycemia and have evolved over the last decade. The ASPIRE study, demonstrated in TID users of Paradigm, Veo with the LGS feature on, reduced the area under the curve (AUC) for nocturnal events of hypoglycemia by 37.5% when compared to the control group (980±1200 mg/dL [54.4±66.6 mmol/L]<min vs 1568±1995 mg/dL [87.0±110.7 mmol/L]<min) (p<0.001), reducing interstitial glucose below 59 mg/dL by 41.9%. The group with this active function also reported reduction in episodes of nocturnal hypoglycemia without increasing levels of A1c (0.00%±0.44% vs −0.04%±0.42%; 95% CI, −0.05 to 0.15).35

Long-term studies in real population at high risk of hypoglycemia documented a significant reduction in the incidence of severe hypoglycemia and UH presented at an early stage from 80.1% to 10.8% and 66.6% to 2.7%, respectively (p<0.001), reducing interstitial glucose by 59 mg/dL to below 60 mg/dL with mean suspension time of 36.1±23.6 min and 8.9% of patients reached values lower than 50 mg/dL.38 Preliminary data from 54 T1D patients with baseline A1c of 8.0%±1.3% after initiation of integrated therapy with MiniMed 640G with SmartGuard show that at 3 months of follow-up the A1c decreases to 7.34±0.94 (p=0.0001), and the incidence of severe hypoglycemia significantly reduced from 1.11±0.05 to 0.037±0.27 episodes per patient during 3 months (p<0.0001), with a significant reduction in AUC <70 mg/dL from 1.39±3.14 to 0.48±0.63 (p=0.048).39

The Medtronic Hybrid Closed-Loop System included the MiniMed 670G, close loop algorithm, and CGM display for investigational fourth-generation subcutaneous glucose sensor and transmitter. They designed a study where the primary end point was to establish its safety for unsupervised use in patients ≥14 years. In the study phase, compared to baseline, mean A1c decreased from 7.4%±0.9% to 6.9%±0.6% (p<0.001), and sensor glucose variability measured by coefficient of variation decreased from 0.38 to 0.35 (p<0.001). There was no diabetic ketoacidosis, severe hypoglycemia, or serious device-related adverse event during 12,389 patient-days. This device was associated with less exposure to hypo- and hyperglycemia, and allows to safely achieve ADA-recommended A1C goals;40 with this study, this device was approved by FDA on October 2016.

In conclusion, the implementation of RT-CGM in clinical practice and the development of integrated devices have allowed the design of different algorithms involving the use of alarms and suspension of insulin infusion, achieving A1c goals with reduction in episodes of severe hypoglycemia in diabetic patients of high risk.

### Reduction of glycemic variability

Glycemic variability is defined as fluctuations in glucose levels, intra- and interday, and its association with endothelial damage, increase in free radical production, and its impact on microvascular complications are debated.41 However, different publications highlight the importance of glycemic variability as a predictor of hypoglycemia independently of A1c levels.42–47 Monnier described the relationship between glycemic variability defined as the standard deviation (SD)
with respect to the mean value of glucose and hypoglycemia, reporting that the risk of hypoglycemia is reduced to a minimum when SD is <1.7 mmol/L (21.06 mg/dL). This author recently published a study including T1D and T2D patients, in which he concluded that the variability measured by the percentage of coefficient of variation is higher in patients diagnosed with T1D with a cutoff point of 36%, which is associated more frequently with hypoglycemia. Other studies have described a strong correlation between SD and baseline. Studies have been conducted in countries such as Sweden, Australia, and Colombia to evaluate the cost-effectiveness of this technology compared to SMBG in T1D patients, and they found that the use of SAP therapy is associated with an increase of 0.76 vs 0.12 years of life adjusted for quality compared to CSII by itself.

In the JDRF study, CGM satisfaction was higher for patients using RT-CGM 6 or more days per week. Also, higher QoL scores in different populations including pediatric patients were associated with more frequent CGM use, suggesting that compliant patients may perceive more benefits from the use of SAP therapy.

In a study conducted in Colombia, using the CORE Diabetes Model, an increase in the average life expectancy was calculated in 3.51 years (95% CI, 3.47–3.55) and in 3.81 years of life adjusted for additional quality in users of sensor augmented pump therapy (SAPT) compared to MDI. In patients treated with SAPT, there was a delay in the occurrence of complications related to poor metabolic control between 1.15 and 1.74 years, with a mean time free of complications of 4.05 years. The average time free of neuropathy, proteinuria, and proliferative retinopathy was 4.5, 4.79, and 4.91 years, respectively; additionally, the cumulative incidence of end-stage renal disease was 10.1% vs 18.5% when compared to MDI. When performing the cost-effectiveness analysis, the costs derived from the use of this technology were partially offset by the savings attributable to the reduction of microvascular complications.

Similar studies have been performed in a population at high risk for severe hypoglycemia evaluating SAP+LGS (Medtronic Paradigm Veo System; Medtronic) compared with standard therapy and SMBG, documenting that SAP+LGS is cost-effective in this population achieving a cost-effectiveness per event of severe hypoglycemia, saving up to 18,257 Australian dollars in patients over 12 years, concluding that the increase in costs of SAPT is partially offset by the reduction in costs related to the treatment of hypoglycemia events. Although these analyses should be performed according to different health systems, these studies suggest that the use of SAPT is a cost-effective therapy, related to the delay in the appearance and progression of microvascular complications and the reduction in episodes of hypoglycemia. The publication of these works allowed the inclusion of this technology by the health system of countries such as Colombia, where the therapy is covered in its entirety. However, there are some limitations with current

**QoL and cost-effectiveness**

RT-CGM and SAP therapy is a tool available in different countries, but its cost has made it difficult to implement in different health systems; however, many efforts have been made in evaluating the real costs including those resulting from an episode of severe hypoglycemia, which includes QoL, hospitalization, mortality, morbidity, labor abstention, or poor metabolic control and its complications. Studies have been conducted in countries such as Sweden, Australia, and Colombia to evaluate the cost-effectiveness of this technology compared to SMBG in T1D patients, and they found that the use of SAP therapy is associated with an increase of 0.76 vs 0.12 years of life adjusted for quality compared to CSII by itself.

In the JDRF study, CGM satisfaction was higher for patients using RT-CGM 6 or more days per week. Also, higher QoL scores in different populations including pediatric patients were associated with more frequent CGM use, suggesting that compliant patients may perceive more benefits from the use of SAP therapy.

In a study conducted in Colombia, using the CORE Diabetes Model, an increase in the average life expectancy was calculated in 3.51 years (95% CI, 3.47–3.55) and in 3.81 years of life adjusted for additional quality in users of sensor augmented pump therapy (SAPT) compared to MDI. In patients treated with SAPT, there was a delay in the occurrence of complications related to poor metabolic control between 1.15 and 1.74 years, with a mean time free of complications of 4.05 years. The average time free of neuropathy, proteinuria, and proliferative retinopathy was 4.5, 4.79, and 4.91 years, respectively; additionally, the cumulative incidence of end-stage renal disease was 10.1% vs 18.5% when compared to MDI. When performing the cost-effectiveness analysis, the costs derived from the use of this technology were partially offset by the savings attributable to the reduction of microvascular complications.

Similar studies have been performed in a population at high risk for severe hypoglycemia evaluating SAP+LGS (Medtronic Paradigm Veo System; Medtronic) compared with standard therapy and SMBG, documenting that SAP+LGS is cost-effective in this population achieving a cost-effectiveness per event of severe hypoglycemia, saving up to 18,257 Australian dollars in patients over 12 years, concluding that the increase in costs of SAPT is partially offset by the reduction in costs related to the treatment of hypoglycemia events. Although these analyses should be performed according to different health systems, these studies suggest that the use of SAPT is a cost-effective therapy, related to the delay in the appearance and progression of microvascular complications and the reduction in episodes of hypoglycemia. The publication of these works allowed the inclusion of this technology by the health system of countries such as Colombia, where the therapy is covered in its entirety. However, there are some limitations with current

**QoL and cost-effectiveness**

RT-CGM and SAP therapy is a tool available in different countries, but its cost has made it difficult to implement in different health systems; however, many efforts have been made in evaluating the real costs including those resulting from an episode of severe hypoglycemia, which includes QoL, hospitalization, mortality, morbidity, labor abstention, or poor metabolic control and its complications. Studies have been conducted in countries such as Sweden, Australia, and Colombia to evaluate the cost-effectiveness of this technology compared to SMBG in T1D patients, and they found that the use of SAP therapy is associated with an increase of 0.76 vs 0.12 years of life adjusted for quality compared to CSII by itself.

In the JDRF study, CGM satisfaction was higher for patients using RT-CGM 6 or more days per week. Also, higher QoL scores in different populations including pediatric patients were associated with more frequent CGM use, suggesting that compliant patients may perceive more benefits from the use of SAP therapy.

In a study conducted in Colombia, using the CORE Diabetes Model, an increase in the average life expectancy was calculated in 3.51 years (95% CI, 3.47–3.55) and in 3.81 years of life adjusted for additional quality in users of sensor augmented pump therapy (SAPT) compared to MDI. In patients treated with SAPT, there was a delay in the occurrence of complications related to poor metabolic control between 1.15 and 1.74 years, with a mean time free of complications of 4.05 years. The average time free of neuropathy, proteinuria, and proliferative retinopathy was 4.5, 4.79, and 4.91 years, respectively; additionally, the cumulative incidence of end-stage renal disease was 10.1% vs 18.5% when compared to MDI. When performing the cost-effectiveness analysis, the costs derived from the use of this technology were partially offset by the savings attributable to the reduction of microvascular complications.

Similar studies have been performed in a population at high risk for severe hypoglycemia evaluating SAP+LGS (Medtronic Paradigm Veo System; Medtronic) compared with standard therapy and SMBG, documenting that SAP+LGS is cost-effective in this population achieving a cost-effectiveness per event of severe hypoglycemia, saving up to 18,257 Australian dollars in patients over 12 years, concluding that the increase in costs of SAPT is partially offset by the reduction in costs related to the treatment of hypoglycemia events. Although these analyses should be performed according to different health systems, these studies suggest that the use of SAPT is a cost-effective therapy, related to the delay in the appearance and progression of microvascular complications and the reduction in episodes of hypoglycemia. The publication of these works allowed the inclusion of this technology by the health system of countries such as Colombia, where the therapy is covered in its entirety. However, there are some limitations with current
continuous glucose monitoring devices, including relatively short sensor lifetime and daily self-monitoring of blood glucose for device calibration to ensure sensor accuracy and inexperience of physicians in the interpretation of CGM results, which have restricted their widespread use.\(^3,^3\)

Conclusion

The CGM devices allow clinicians to assess glycemic control, detect hypoglycemia, especially nocturnal, and provide the clinician with additional information including glycemic variability. The development of integrated therapies allows the achievement of strict glycemic control goals with reduction in episodes of severe hypoglycemia in a high-risk population. Although the cost of therapy is one of the main limitations in its use, SAPT has proven to be cost-effective in several countries in terms of increased life expectancy, delayed onset, and progression of microvascular complications with reduced cost of episodes of severe hypoglycemia, offering a safe alternative in the treatment of patients with diabetes. However, to push this technology for a broader use, the development of cheaper and more accurate sensors is needed, and also more physicians should be familiarized with the advantages of using this technology.

Acknowledgment

We are grateful to our team from the diabetes center at Hospital Universitario San Ignacio.

Disclosure

The authors declare the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: AMG reports speaker fees from Novo Nordisk, Eli Lilly, MSD, Novartis, and Medtronic and research grants from Medtronic, Novartis, Novo Nordisk, and Abbott. DCH reports speaker fees and research grants from Novo Nordisk. The authors report no other conflicts of interest in this work.

References

1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet (London, England). 1998;352(9131):837–853.
2. Nathan DM, Gough S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–986.
3. Bergenstal RM, Tamborlane WV, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363(4):311–320.
4. Tamborlane WV, Beck RW, Bode BW, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359(14):1464–1476.
5. Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ. 2011;343:d3805.
6. Ana María Gómez Medina AMS. Real time continuous blood glucose monitoring: the combined use of continuous insulin infusion is essential. Avances en Diabetología. 2011;27(4):143–150.
7. Hoeks LB, Greven WL, de Valk HW. Real-time continuous glucose monitoring system for treatment of diabetes: a systematic review. Diabet Med. 2011;28(4):386–394.
8. Rodbard D. Continuous glucose monitoring: a review of successes, challenges, and opportunities. Diabetes Technol Ther. 2016;18(Suppl 2):S3–S13.
9. Keenan DB, Mastrotorto JJ, Voskanyan G, Steil GM. Delays in minimally invasive continuous glucose monitoring devices: a review of current technology. J Diabetes Sci Technol. 2009;3(5):1207–1214.
10. Kulcu E, Tamada JA, Reach G, Potts RO, Lesko MJ. Physiological differences between interstitial glucose and blood glucose measured in human subjects. Diabetes Care. 2003;26(8):2405–2409.
11. Pfutzner A, Klonoff DC, Pardo S, Parkes JL. Technical aspects of the Parkes error grid. J Diabetes Sci Technol. 2013;7(5):1275–1281.
12. Bailey TS, Grenberger G, Bode BW, et al. American association of clinical endocrinologists and American college of endocrinology 2016 outpatient glucose monitoring consensus statement. Endocr Pract. 2016;22(2):231–261.
13. Aberer F, Hajnsek M, Rumpler M, et al. Evaluation of subcutaneous glucose monitoring systems under routine environmental conditions in patients with type 1 diabetes. Diabetes obes Metab. 2017;19(7):1051–1055.
14. Fokkert MJ, van Dijk PR, Edens MA, et al. Performance of the FreeStyle Libre Flash glucose monitoring system in patients with type 1 and 2 diabetes mellitus. BMJ Open Diabetes Res Care. 2017;5(1):e000320.
15. Gomez AM, Marin Sanchez A, Munoz OM, Colon Pena CA. Numerical and clinical precision of continuous glucose monitoring in Colombian patients treated with insulin infusion pump with automated suspension in hypoglycemia. Endocrinol Nutr. 2015;62(10):485–492.
16. Vaddiraju S, Burgess DJ, Tomazos I, Jain FC, Papadimitrakopoulos F. Technologies for continuous glucose monitoring: current problems and future promises. J Diabetes Sci Technol. 2010;4(6):1540–1562.
17. Bailey T, Bode BW, Christiansen MP, Klaiff LI, Alva S. The performance and usability of a factory-calibrated flash glucose monitoring system. Diabetes Technol Ther. 2015;17(11):787–794.
18. Kroppf J, DeVries JH. Continuous glucose monitoring, future products, and update on worldwide artificial pancreas projects. Diabetes Technol Ther. 2016;18(Suppl 2):S253–S263.
19. Haak T, Hanaire H, Ajan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8(1):55–73.
20. Bonora B, Maran A, Ciciliot S, Avogaro A, Fadini GP. Head-to-head comparison between flash and continuous glucose monitoring systems in outpatients with type 1 diabetes. J Endocr Invest. 2016;39(12):1391–1399.
21. Battelino T, Conget I, Olsen B, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia. 2012;55(12):3155–3162.
22. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the diamond randomized clinical trial. JAMA. 2017;317(4):371–378.
23. Soupal J, Petruzeltova L, Flekac M, et al. Comparison of different treatment modalities for type 1 diabetes, including sensor-augmented insulin regimens, in 52 weeks of follow-up: a COMISAIR Study. Diabetes Technol Ther. 2015;17(11):787–794.
24. Standards of medical care in diabetes-2017: summary of revisions. Diabetes Care. 2017;40(Suppl 1):S4–S5.
25. Hay LC, Wilmhurst EG, Fulcher G. Unrecognized hypo- and hyperglycemia in well-controlled patients with type 2 diabetes mellitus: the results of continuous glucose monitoring. Diabetes Technol Ther. 2003;5(1):19–26.

26. Khunti K, Davies M, Majeed A, Thorsted BL, Wolden ML, Paul SK. Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care. 2015;38(2):316–322.

27. Fahrmann ER, Adkins L, Loader CJ, et al. Severe hypoglycemia and coronary artery calcification during the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study. Diabetes Res Clin Pract. 2015;107(2):280–289.

28. Kramer CK, Choi H, Zinman B, Retnakaran R. Glycemic variability indices obtained by continuous glucose monitoring. Diabetes Technol Ther. 2015;17(6):561–569.

29. Awoniyi O, Rehman R, Dagogo-Jack S. Hypoglycemia in patients with type 1 diabetes: epidemiology, pathogenesis, and prevention. Curr Diabetes Rep. 2015;13(5):669–678.

30. Ly TT, Brnabic AJ, Eggleston A, et al. A cost-effectiveness analysis of sensor-augmented insulin pump therapy and automated insulin suspension versus standard pump therapy for hypoglycemic unware patients with type 1 diabetes. Value Health. 2014;17(5):561–569.

31. Choudhary P, Olsen BS, Conget I, Welsh JB, Vorrink L, Shin JJ. MiniMed 640G system with SmartGuard for managing blood glucose levels in people with type 1 diabetes. National Institute for Health and Care Excellence, NICE. 2016.

32. Stephan Matthaei. An Evaluation of Novel Glucose Sensing Technology on Hypoglycemia in Type 1 Diabetes (IMPACT). Available from: https://clinicaltrials.gov/ct2/show/NCT02232698. NLM Identifier: NCT02232698. Accessed May 29, 2017.

33. Kim S, Lohrenz AT, Ben-Dor E, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013;369(3):224–232.

34. Deiss D, Bolinder J, Riveline JP, et al. Improved glycemic control in type 1 diabetic patients treated with either insulin pumps or multiple insulin injections for glycemic control in adults with type 1 diabetes: the RealTrend study. Diabetes Technol Ther. 2009;11(12):577–583.

35. Gomez AM, Henao Carrillo DC, et al. Severe hypoglycemia and coronary artery calcification during the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study. Diabetes Res Clin Pract. 2015;107(2):280–289.

36. Gomez AM, Marin Carrillo LF, et al. Long-term efficacy and safety of sensor-augmented insulin pump therapy with low-glucose suspend feature in patients with type 1 diabetes. Diabetes Technol Ther. 2017;19(2):109–114.

37. MiniMed 640G system with SmartGuard for managing blood glucose levels in people with type 1 diabetes. National Institute for Health and Care Excellence, NICE. 2016.

38. Modern Medicine. Continuous glucose monitoring devices. Dovepress. 2017;10:223.
